The First Affiliated Hospital Nanchang Univeristy
Welcome,         Profile    Billing    Logout  
 5 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xiong, Jianping
SAFFRON-301, NCT04921358 / 2022-001779-15: Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Terminated
3
377
RoW
Tislelizumab, Docetaxel, Sitravatinib
BeiGene, BeiGene, Ltd.
Non-Small Cell Lung Cancer (NSCLC)
12/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting
2
103
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
01/25
LM302-01-102, NCT05161390: Study of LM-302 in Patients With Advance Solid Tumors

Active, not recruiting
1/2
206
RoW
LM-302 Injection
LaNova Medicines Zhejiang Co., Ltd.
Advanced Solid Tumor
03/25
06/25
NCT05801094: A Phase I Study of QL1604 for Advanced Solid Tumors

Active, not recruiting
1
71
RoW
QL1604
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
04/23
12/23
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Recruiting
1
196
US, RoW
IPG7236
Nanjing Immunophage Biotech Co., Ltd
Safety Issues, Tolerability, Pharmacokinetics
09/25
12/25

Download Options